YKL-40 in serum: a promising biomarker of juvenile SLE and strongly correlated with disease duration.
| Title: | YKL-40 in serum: a promising biomarker of juvenile SLE and strongly correlated with disease duration. |
|---|---|
| Authors: | Ali AA; Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, P. R., Zhenjiang, China.; Yousef RN; Department of Clinical and Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt. rashanazzih@yahoo.com.; Elsheikh MS; Department of Complementary Medicine, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.; Salamah AR; Department of Molecular Genetics and Enzymology, Human Genetics and Genomic Research Institute, National Research Center, Giza, Egypt.; Wu LL; Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, P. R., Zhenjiang, China.; Alnaggar AR; Internal Medicine Department, Rheumatology and Clinical Immunology Unit, KasrAlainy School of Medicine, Cairo University, Cairo, Egypt.; Khalil NM; Internal Medicine Department, Rheumatology and Clinical Immunology Unit, KasrAlainy School of Medicine, Cairo University, Cairo, Egypt.; Behiry ME; Internal Medicine Department, Rheumatology and Clinical Immunology Unit, KasrAlainy School of Medicine, Cairo University, Cairo, Egypt. |
| Source: | Irish journal of medical science [Ir J Med Sci] 2024 Jun; Vol. 193 (3), pp. 1403-1409. Date of Electronic Publication: 2023 Oct 24. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Royal Academy of Medicine of Ireland Country of Publication: Ireland NLM ID: 7806864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1863-4362 (Electronic) Linking ISSN: 00211265 NLM ISO Abbreviation: Ir J Med Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Dublin : Royal Academy of Medicine of Ireland |
| MeSH Terms: | Chitinase-3-Like Protein 1*/blood ; Biomarkers*/blood ; Lupus Erythematosus, Systemic*/blood; Humans ; Female ; Adolescent ; Adult ; Child ; Young Adult ; Case-Control Studies |
| Abstract: | Background: The biological function of YKL-40 is not well determined in different inflammatory and autoimmune diseases; however, some data highlighted its possible connection with disease activity.; Aim: We investigated the diagnostic utility of serum YKL-40 in patients with SLE and examined its correlation with disease activity. Additionally, we examined any differences in serum YKL-40 levels between juvenile and adult SLE patients.; Methods: We included 78 female patients with SLE and 42 controls. The level of YKL-40 in serum was measured by ELISA.; Results: The serum YKL-40 level in SLE patients was significantly higher compared to the control group (9 (3) ng/mL vs. 5.5 (0.1) ng/mL; p |
| References: | Rheumatology (Oxford). 2021 Jan 5;60(1):231-238. (PMID: 32681176); J Dermatol. 2013 Apr;40(4):294-6. (PMID: 23397985); Scand J Rheumatol. 2005 Jul-Aug;34(4):293-7. (PMID: 16195162); Immunology. 2018 Jun;154(2):186-195. (PMID: 29455468); Caspian J Intern Med. 2019 Winter;10(1):92-97. (PMID: 30858947); J Rheumatol. 2003 Oct;30(10):2147-51. (PMID: 14528508); PLoS One. 2017 Aug 25;12(8):e0183294. (PMID: 28841649); Biochem Biophys Res Commun. 2001 Jul 27;285(4):926-31. (PMID: 11467840); Clin Immunol. 2019 Oct;207:1-9. (PMID: 31255802); Front Immunol. 2021 Dec 20;12:734008. (PMID: 34987500); Brain Pathol. 2012 Jul;22(4):530-46. (PMID: 22074331); Pol Arch Med Wewn. 2009 Dec;119(12):777-84. (PMID: 20010462); Front Neurol. 2021 Jun 18;12:702431. (PMID: 34220697); Lupus. 2021 Aug;30(9):1526-1535. (PMID: 33951965); PLoS One. 2018 Dec 18;13(12):e0208132. (PMID: 30562343); Rheumatol Int. 2001 Jul;20(5):192-6. (PMID: 11518039); Crit Rev Clin Lab Sci. 2008;45(6):531-62. (PMID: 19003601); Clin Rheumatol. 2019 Jun;38(6):1655-1663. (PMID: 30739212); J Neurotrauma. 2010 Jul;27(7):1215-23. (PMID: 20486806); Int J Mol Sci. 2021 Jul 16;22(14):. (PMID: 34299237); Arthritis Rheum. 2000 Jun;43(6):1233-43. (PMID: 10857782); J Biol Chem. 1993 Dec 5;268(34):25803-10. (PMID: 8245017); Ann Rheum Dis. 2002 Apr;61(4):311-8. (PMID: 11874832); Annu Rev Physiol. 2011;73:479-501. (PMID: 21054166); Nat Rev Rheumatol. 2016 Aug 23;12(9):543-58. (PMID: 27549026); Ann Clin Biochem. 2019 Jan;56(1):95-99. (PMID: 30019588); Cureus. 2022 Mar 7;14(3):e22938. (PMID: 35399432); Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. (PMID: 31385462); J Rheumatol. 2003 Mar;30(3):449-54. (PMID: 12610799); J Investig Med High Impact Case Rep. 2018 Nov 15;6:2324709618812196. (PMID: 30480003); Int J Biol Sci. 2022 May 21;18(9):3731-3746. (PMID: 35813465); Discov Med. 2012 Feb;13(69):151-8. (PMID: 22369974); J Biol Chem. 2005 Dec 16;280(50):41213-21. (PMID: 16234240); Biomark Insights. 2007 May 03;2:128-46. (PMID: 19662198); J Rheumatol. 2000 Feb;27(2):373-6. (PMID: 10685799); J Neuroinflammation. 2010 Jun 11;7:34. (PMID: 20540736); Viruses. 2019 Aug 21;11(9):. (PMID: 31438470); J Rheumatol. 2017 Sep;44(9):1394-1401. (PMID: 28711881); Adv Rheumatol. 2021 Jul 5;61(1):44. (PMID: 34225813) |
| Contributed Indexing: | Keywords: Disease duration; Juvenile onset SLE; SLE; YKL-40 |
| Substance Nomenclature: | 0 (Chitinase-3-Like Protein 1); 0 (Biomarkers); 0 (CHI3L1 protein, human) |
| Entry Date(s): | Date Created: 20231024 Date Completed: 20240526 Latest Revision: 20240530 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11128401 |
| DOI: | 10.1007/s11845-023-03545-w |
| PMID: | 37874503 |
| Database: | MEDLINE |
Journal Article